Artificial Intelligence
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Today's issue
Refine Search
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
Privately-held Boston-based biopharma FogPharma has announced a name change and unveiled a new AI-based platform. 11 November 2024
Pharmaceutical
Oxford Cannabinoid Technologies (OCT) today announced the successful completion of 'proof of concept' of its AI-enabled drug discovery asset, which it is developing in collaboration with New York-based tech consultancy, Hypatia AI. 4 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted a Rare Pediatric disease designation for BPM31510T, an investigational treatment for epidermolysis (EB) from BPGbio. 4 November 2024
Biotechnology
Dyno Therapeutics has recently announced the formation of a new strategic partnership with Swiss pharma giant Roche to develop adeno-associated virus (AAV) gene therapy vectors to target neurological diseases. 1 November 2024
Biotechnology
US artificial intelligence (AI) to gene therapy focussed biotech Dyno Therapeutics today announced its second research collaboration with Roche to develop next-generation adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases. 24 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
California, USA-based biotech Terray Therapeutics, yesterday announced the closing of an oversubscribed Series B funding of $120 million. 18 October 2024
Pharmaceutical
British artificial intelligence specialist BenevolentAI has announced the return of its founder, Ken Mulvany, as executive chairman. 18 October 2024
Pharmaceutical
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024
Pharmaceutical
Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly. 10 October 2024
Biotechnology
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Pharmaceutical
The UK has launched a new Regulatory Innovation Office (RIO), with the goal of accelerating new technologies, particularly in sectors like biotech and healthcare, by reducing regulatory barriers. 9 October 2024
Biotechnology
Evaxion Biotech has entered into an option and license agreement with MSD (tradename of Merck & Co outside of the USA and Canada), for two pre-clinical vaccine candidates. 26 September 2024
Biotechnology
Danish CNS specialist Lundbeck and US privately-held biotech Iambic Therapeutics today announced a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. 26 September 2024
Pharmaceutical
USA-based Generate:Biomedicines (Generate) today announced a multi-target collaboration with Swiss pharm giant Novartis to discover and develop protein therapeutics across multiple disease areas. 24 September 2024
Biotechnology
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Biotechnology
Californian companies Gilead Sciences and Genesis Therapeutics have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets. 10 September 2024
Biotechnology
Danish clinical-stage techbio firm Evaxion Biotech, which is developing AI-Immunology powered vaccines, announced new clinical Phase II data for its lead compound EVX-01. 9 September 2024
Biotechnology
ZipBio, a newly launched start-up based in Seattle, USA, is aiming to set a new standard in the development of biologics and gene therapies by utilizing generative AI technology. 9 September 2024
Pharmaceutical
As the initial waves of the coronavirus pandemic hit in early 2020, pharma and biotech stocks saw major declines as investors digested the likely impact. 11 November 2021
Pharmaceutical
Japanese drugmaker Sumitomo Dainippon Pharma and Nashville, USA-based BehaVR have signed definitive agreements to develop and commercialize both prescription digital therapeutics and general wellness products for treatment of social anxiety disorder (SAD), generalized anxiety disorder (GAD), and major depressive disorder (MDD) with the goal of bringing much needed tools to tackle the escalating global anxiety and depression crisis. 20 October 2021
Pharmaceutical
New European Union (EU) regulation requires life sciences companies’ data in the clinical trial master file (TMF) to remain secure, accessible, and usable for a period of 25 years. 15 October 2021
Biotechnology
Oxford, UK-based Exscientia, which develops and licenses therapies designed with its artificial intelligence (AI) drug discovery platform, today announced the pricing of its upsized initial public offering (IPO) in the USA of 13,850,000 American Depositary Shares (ADSs) representing 13,850,000 ordinary shares at an initial public offering price of $22.00 per ADS, for total gross proceeds of around $304.7 million. 1 October 2021
Pharmaceutical
Research undertaken at the University of Bristol, UK, paves the way for a novel artificial intelligence (AI)-driven platform for growing and treating virtual tumors. 22 September 2021
Pharmaceutical
For many years, artificial intelligence (AI), in particular machine learning, have been touted as potentially transformational technologies for drug discovery and development. 16 August 2021
Pharmaceutical
Raman Sehgal, the founder of ramarketing, provides an Expert View on how pharmaceutical and life sciences businesses can market themselves in the post-pandemic environment. 10 August 2021
Biotechnology
Japanese drug major Ono Pharmaceutical has entered into a research collaboration agreement with Cambridge, UK-based Healx Limited, an artificial intelligence (AI)-driven biopharmaceutical company, on Healx’ unique AI technology to jointly discover and develop novel, efficacious treatment drugs for diseases with unmet medical needs. 6 August 2021
Pharmaceutical
Some digital health tools are becoming integral parts of mainstream medicine, according to findings released today by the IQVIA Institute for Human Data Science in a new report. 23 July 2021
Pharmaceutical
Arkivum, a University of Southampton spin-out, has just published a new report “Good data in the age of digital transformation” tracking the progress of 300 global life sciences and biopharma companies over the past year as they implement digital transformation strategies and unlock the potential of their clinical trial data. 2 July 2021
Pharmaceutical
The research and development of pharmaceuticals is a costly, lengthy, and high-risk venture, spread over four stages of studies: drug discovery, preclinical research, clinical research, and post-marketing studies on safety and effectiveness. The journey of a new drug to the market is estimated to take approximately 10 years and cost billions of US dollars, says Dr Nicola Davies in her exclusive article on the US Food and Drug Administration.1 7 June 2021
Pharmaceutical
USA-headquartered digital medicines company Akili Interactive, maker of EndeavorRx, the first and only prescription video game treatment, today announced $160 million in combined equity and debt financing. 26 May 2021
Pharmaceutical
AJ Ploszay, vice president of digital strategy, IQVIA, provides an Expert View on how the precedent for consumer buying set by companies like Amazon, further accelerated by the digital buying trends driven by COVID-19, are influencing a similar shift in the commercial pharma space. 20 May 2021
Pharmaceutical
The pharmaceutical industry is now frequently the number one target of cybercriminals around the world, as drugmakers move toward increased digitization and storing valuable data online. 9 February 2021
Biotechnology
AstraZeneca has selected a novel chronic kidney disease (CKD) target to advance to its drug development portfolio, under its collaboration with fellow UK-based artificial intelligence (AI) company BenevolentAI. 28 January 2021
Pharmaceutical
Novartis’ Steven Baert, chief people and organization officer, and Elizabeth Theophille, chief technology transformation officer, provide an Expert View predicting what will dictate developments in the pharmaceutical and healthcare industries in 2021. 19 January 2021
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze